CD4 and pulmonary arterial hypertension: Thus, we leveraged the large CLEOPAHTRA trial (NCT04282434 at clinicaltrials.gov) of well-phenotypes patients to test the hypothesis that PAH patients are distinct from healthy controls by virtue of circulating CD4+ T cell DNA methylation signatures, which, in turn, may be relevant for phenotyping and prognostication of affected patients.